FDA Approves First-Ever RSV Vaccine for Older Adults
TL;DR Summary
The FDA has approved the first respiratory syncytial virus (RSV) vaccine, Arexvy, for use in individuals 60 years of age and older. RSV is a highly contagious virus that causes infections of the lungs and breathing passages, and is a common cause of lower respiratory tract disease (LRTD) in older adults. Arexvy significantly reduced the risk of developing RSV-associated LRTD by 82.6% and reduced the risk of developing severe RSV-associated LRTD by 94.1%. The vaccine's safety and effectiveness is based on an ongoing, randomized, placebo-controlled clinical study.
- FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine FDA.gov
- FDA approves first vaccine for RSV, a moment six decades in the making CNN
- FDA approves GSK's RSV vaccine for older adults, world's first shot against virus CNBC
- FDA approves first-ever RSV vaccine, shots to be available for older adults msnNOW
- First vaccine targeting RSV wins FDA approval. More are coming. The Washington Post
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
3 min
vs 4 min read
Condensed
88%
702 → 87 words
Want the full story? Read the original article
Read on FDA.gov